Aelis Farma
AEFAR.PAN/A
Euronext ParisBiotechnology🇫🇷Europe
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AEFAR.PA News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
AEF0217 100 µg
Down Syndrome (Trisomy 21)
AEF0117
Marijuana Abuse
AEF0217
Down Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AEF0217 100 µg | Phase 2 | Down Syndrome (Trisomy 21) | - | - |
AEF0117 | Phase 2 | Marijuana Abuse | - | - |
AEF0217 | Phase 2 | Down Syndrome | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply